Costs, quality of life, treatment satisfaction and compliance in patients with β-thalassemia major undergoing iron chelation therapy: The ITHACA study

Current Medical Research and Opinion

Volumn 24, Issue 7, 2008, Pages 1905-1917

  Scalone, Luciana ^a,b   Mantovani, Lorenzo G ^a,b   Krol, Marieke ^c   Rofail, Diana ^d   Ravera, Simona ^e   Bisconte, Maria Grazia ^f   Borgna Pignatti, Caterina ^g   Borsellino, Zelia ^h   Cianciulli, Paolo ⁱ   Gallisai, Domenico ^j   Prossomariti, Luciano ^k   Stefàno, Ippazio ^l   Cappellini, Maria D ^e  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CHARTA Foundation (Member of COPERA)   (Italy)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d MAPI VALUES   (United States)

^e UNIVERSITY OF MILAN   (Italy)

^f Azienda Ospedaliera Cosenza   (Italy)

^g Arcispedale S Anna Dipartimento di Medicina Clinica Sperimentale   (Italy)

^h ARNAS Civico   (Italy)

ⁱ S EUGENIO HOSPITAL   (Italy)

^j UNIVERSITY OF SASSARI   (Italy)

^k CARDARELLI HOSPITAL   (Italy)

^l Azienda Ospedaliera SS Annunziata   (Italy)

more..

Author keywords

thalassemia; Compliance; Cost analysis; HRQoL; Iron chelation therapy; Satisfaction

Indexed keywords

DEFERIPRONE; DEFEROXAMINE;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; CLINICAL EFFECTIVENESS; COST OF ILLNESS; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; IRON CHELATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MONOTHERAPY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITATIVE ANALYSIS; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TREATMENT OUTCOME; WELLBEING;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; ITALY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PERSONAL SATISFACTION; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 47949125257     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802160834     Document Type: Article

References (35)

1. Wolman IJ. Transfusion therapy in Cooley's anemia: growth and health as related to long-range hemoglobin levels, a progress report. Ann NY Acad Sci 1964;119:736-52
2. Piomelli S, Danoff SJ, Becker MH, et al. Prevention of bone malformations and cardiomegaly in Cooley's anemia by early hypertransfusion regimen. Ann NY Acad Sci 1969;165:427-36
3. Barry M, Flynn DN, Letsky EA, et al. Long-term chelation therapy in thalassemia major: effect on liver iron concentration, liver histology and clinical progress. Br Med J 1974;2:16-20
4. Hussain MA, Green N, Flynn DM, et al. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload. Lancet 1976;2:1278-80
5. Modell CB, Beck J. Long-term desferrioxamine therapy in thalassemia. Ann NY Acad Sci 1974;232:201-10
6. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet 1989;8653:27-30
7. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-93
8. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann NY Acad Sci 1998;850:227-31
9. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous β-thalassemia. New Engl J Med 1994;331:574-8
10. Cohen AR, Galanello R, Piga V, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003;102:1583-7
11. Piga A, Gaglioti C, Fogliacco E, et al. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003;88:489-96
12. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in β-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006;107:3738-44
13. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007;115:1876-84
14. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;107:3455-62
15. Woods K, Karrison T, Koshy M, et al. Hospital utilization patterns and costs for adult sickle cell patients in Illinois. Public Health Rep 1997;112:44-51
16. Ginsberg G, Tulchinsky T, Filon D, et al. Cost benefit analysis of a national thalassaemia prevention programme in Israel. J Med Screen 1998;5:120-6
17. Nietert PJ, Abboud MR, Zoller JS, et al. Costs, charges, and reimbursements for persons with sickle cell disease. J Pediatr Hematol Oncol 1999;21:389-96
18. Karnon J, Zeuner D, Brown J, et al. Lifetime treatment costs of beta-thalassaemia major. Clin Lab Haematol 1999;21:377-85
19. Wayne AS, Schoenike SE, Pegelow CH. Financial analysis of chronic transfusion for stroke prevention in sickle cell disease. Blood 2000;96:2369-72
20. Mayer ML, Konrad TR, Dvorak CC. Hospital resource utilization among patients with sickle cell disease. J Health Care Poor Underserved 2003;14:122-35
21. Desrosiers MP, Payne K, Proskorovsky I, et al. Estimated total annual costs of infused iron chelation therapy in the United Kingdom. Poster presented at the 11th Congress of the European Hematology Association (EHA). Abstract 0810 published in Haematologica/The Hematology Journal 2006;91(s1), (EHA), Amsterdam, The Netherlands, 17th June 2006
22. Brun-Strang C, Bachir D, De Montalembert M, et al. Socioeconomic impact of infused iron chelation therapy in France: ISOSFER study results. Poster presented at the American Society of Hematology (ASH) Congress in 2006. Abstract 3354 published in Bloodl 2006; 108, 48th Annual Congress, Orlando, Florida, US, 9-11 December 2006
23. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. Oxford (UK): Oxford University Press; 1997
24. Van Roijen L, Essink-Bot ML, Koopmanschap MA, et al. Labor and health status in economic evaluation of health care. The Health and Labor Questionnaire. Int J Technol Assess Health Care 1996;12:405-15
25. Ware Jr J, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: a user's manual. Boston (MA): The Health Institute; 1994
26. Ware Jr J, Gandek B, Kosinski M, et al. The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA project [International Quality of Life Assessment]. J Clin Epidemiol 1998;51:1167-70
27. Brooks R. Euroqol: the current state of play. Health Policy 1996;37:53-72
28. Apolone G, Mosconi P, Ware Jr JE. Questionario sullo Stato di Salute SF-36. Manuale d'uso e guida all'interpretazione dei risultati. Milano (Italy): Guerini e Associati; 1997
29. Gringeri A, Mantovani LG, Scalone L, et al. Cost of care and quality of life for patients with haemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003;102:2358-63
30. Mantovani LG, Scalone L, Mannucci PM, et al. The cost of care of hemophilic patients without inhibitors: the COCHE study. Poster presented at the World Federation of Hemophilia (WFH) Congress in 2006. Abstract 28 PO 880, published in Haemophilial 2006;12(S2):133-5
31. Abetz L, Baladi JF, Jones P, et al. The development of a treatment satisfaction questionnaire for iron overload (IO) patients on chelation therapy (CT). International Society for Pharmacoeconomics and Outcomes Research 8th Annual European Congress, November 6-8, 2005; Florence, Italy. Abstract n. PMC27 published in Value in Health 2005;8;A72
32. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951;16:297-334
33. Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of non-compliance with iron chelation therapy in patients with transfusion- dependent thalassemia: a literature review. Transfusion 2007;47:1919-29
34. Angelucci E, Barosi G, Camaschella C, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica 2008;93:1-12
35. Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther 2007;29:909-17